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Today 2.2million bone-graft surgeries have been performed annually onworld
basis, resulting in a demand for bone graft that far exceeds supply. As a
consequence, a variety of biomaterial scaffolds have been developed for
tissue engineering of bone healing and repair. The structure of scaffolds is of
particular importance in scaffolds-based tissue engineering since it affects the
functionality of the tissue-engineering construct. Preclinical investigations of
bone regeneration with scaffolds have been performed using various animal
models, and bone regeneration has been evaluated by different methodolo-
gies. Micro-CT imaging provides an important analytical tool capable of
quantifyingbone tissues in vitro, andmore importantly ofmonitoringbone for-
mation in vivo longitudinally. This technique provides a fast, nondestructive,
and 3D quantification of bone scaffolds, and bone formation and ingrowth.
Currently, methods for quantitatively assessing macrostructure include con-
ventional radiographs, dual-energy X-ray absorptiometry (DEXA) and
computed tomography (CT), particularly volumetric quantitative computed
tomography (vQCT). Methods for non-invasive assessing microarchitecture of
bone tissues include high-resolution peripheral quantitative computed to-
mography (HR-pQCT), microcomputed tomography (micro-CT), high-resolu-
tion magnetic resonance (HR-MR), micromagnetic resonance (micro-MR),
synchrotron radiation computed tomography (SR-CT). Methods for non-
invasive assessing ultrastructure of bone tissues can be achieved by nano-CT
scanner and SR-CT. vQCT, HR-pQCTand HR-MR are generally applicable in vivo
as clinical tools for assessment of bone diseases and bone repair; micro-CTand
micro-MR are applicable both in vivo in patients and in animals, and in vitro for
animal sample and humanbone biopsy aswell; and SR-CT is applicable in vitro.
During the last decades, great progresses in imaging techniques have been
achieved allowing us to monitor bone microarchitectural changes in vivo in a
non-invasive manner and ultrastructural changes in vitro with high accuracy.
Imaging can reach a high resolution as micrometer or even nanometer scale.
However, more efforts are demanded to improve imaging techniques.
This review concentrates on quantification of in vivo micro-CT imaging for
small animal longitudinal studies; in vitro micro-CT and nano-CT imaging
for sample assessments; and HR-pQCT for clinical trials. These imaging tech-
niques allow us to analyze hierarchical structures of cancellous bone,
cortical bone, and bone regeneration, and to characterize them into organ
level, tissue level, and cell level.
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Muscle atrophy is common in aging (sarcopenia), as a consequence of fractures
or bed rest (disuse atrophy) and as a result of chronic illnesses like cancer,
COPD and chronic infections (cachexia). Loss of mobility due to muscle
weakness and atrophy is a common and debilitating problem across all ages
leading to increasedmorbidity andmortality. Although there is provenefficacy
of resistance exercise, this is very hard to scale up to population-level
treatment. There is no pharmacological treatment that can reverse muscle
atrophy. Pharmacological treatment can be aimed at blocking the diseases
related atrophy, stimulating amuscle hypertrophy, encouraging satellite cells
to undergo cell differentiation, stimulating fiber-type switch ormitochondrio-
genesis, and at improving neuromuscular coupling.
Disease progression and drug treatment effects onmuscle can be evaluated in a
large array of rodent models. These include sarcopenia as a result of
spontaneous aging, dexamethasone-induced myopathy, mouse boot immobili-
zation, denervation or nerve crush-damage induced atrophy, as well as cancer
or adjuvant arthritis induced cachexia. Muscle volume can be determined non-
invasively with high precision in rodent models using proton MRI and qNMR.
Quantification of muscle fiber type composition requires tissue sampling and
automated quantification by histomorphometry. Methods to quantify energy
metabolism using 31P magnetic resonance spectroscopy (31P MRS) for wide-
spreaduse in small animalsare indevelopment.Thereappears tobegoodagree-
ment between changes in O2 saturation and phosphocreatine concentrations.
The ultimate therapeutic goal in treating muscle wasting disorders is the
improvement in muscle function which, unfortunately, oftentimes correlates
poorly with changes inmuscle volume as determined by non-invasive imaging.
For this reason, physical performance testing (treadmill performance testing),
determination of muscle strength (evoked muscle force and fatigue),
endurance exercise and gait analysis remain essential tools for monitoring of
disease progression and the determination of therapeutic effects, which at
present cannot be replaced by non-invasive bioimaging methods. In the
future, a minimally invasive ‘optical’ biopsy with the sarcoscope, may be able
to assess muscle contractile dynamics in mice and humans.
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